Clinical Trial

A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors

Study acronym: HiLoGlio

Recruiting

Summary

There is a high medical need to improve treatment outcome for high-grade and low-grade glioma since no curative treatment is available. To achieve this goal, a broader understanding is needed of the causes of inter-and intratumoral heterogeneity; glioma dedifferentiation and invasion; the major determinants of malignancy and treatment failure in glioma patients. Patient-derived organoid (PDOs) of high-grade gliomas and low-grade gliomas will be used to identify the mechanisms that underlie this malignant behaviour and treatment resistance. This insight may be used to develop patient avatars to simultaneously test multiple new treatment modalities that are predictive for survival and quality of life of glioma patients.

Protocol Amendment History 4 amendments

This ClinicalTrials.gov record has been amended 4 times since 2021-04-26; most recent amendment 2026-01-26.

Status change: Active, Not Recruiting → Recruiting 2024-09-26

Trial Details

NCT Number	NCT04865315
Lead Sponsor	Maastricht Radiation Oncology Collaborators: Maastricht University Medical Center, Zuyderland Medisch Centrum, Ziekenhuis Oost-Limburg
Conditions	Low-grade Glioma, High Grade Glioma
Enrollment	50 participants
Start Date	2022-05-01
Primary Completion	2028-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-01-27